From Idea to Impact: What EsoBiotec’s Billion-Dollar Exit Says About Belgium’s Biotech Ecosystem

This article follows the recent feature in L’Echo on EsoBiotec, a Walloon biotech start-up whose acquisition by AstraZeneca marks a new milestone for Belgium’s life sciences sector. We reflect on what this success story reveals about the country’s growing biotech ecosystem — and how it con...

/en/blog/esobiotecs-billion-dollar-exit-says-about-belgiums-biotech

Link text

Stay connected

Never miss the latest insights, blogs and news. Subscribe to our newsletter.

This article follows the recent feature in L’Echo on EsoBiotec, a Walloon biotech start-up whose acquisition by AstraZeneca marks a new milestone for Belgium’s life sciences sector. We reflect on what this success story reveals about the country’s growing biotech ecosystem — and how it connects to the learning experience offered by the Advanced Master in Biotech and Medtech Ventures (AMBT).

In March 2025, Walloon biotech start-up EsoBiotec was acquired by AstraZeneca for up to $1 billion — a milestone for the Belgian life sciences sector and a reflection of the strength and maturity of its innovation ecosystem.

Founded in 2020, EsoBiotec developed a new approach to cell therapy, making it faster, more scalable, and more accessible. It’s the kind of breakthrough that reflects a broader trend: Belgium is increasingly seen as a hub for biotech entrepreneurship and venture creation.

EsoBiotec’s story also reflects the kind of ecosystem our participants are immersed in during the Advanced Master in Biotech and Medtech Ventures. One of the company’s early backers, InvestSudTech, is both a shareholder in EsoBiotec and a sponsor of the AMBT. Our Academic Director, Marc Dechamps, serves as President of the Board at InvestSudTech, bringing direct industry insight into the classroom.

These connections highlight the value of embedding learning within real-world entrepreneurial contexts. Through the AMBT, participants not only gain business and scientific expertise - they also tap into the networks and perspectives that are shaping the next generation of biotech ventures.

EsoBiotec’s growth was also marked by a strong network of Belgian public and private support. The company benefited from early investments from regional actors like Sambrinvest and InvestSud Tech, and received multiple rounds of funding, including support from Walloon public authorities.

This illustrates the robust financing landscape that is accessible to start-ups operating in life sciences within Belgium, especially those building on deep scientific expertise.

The deal with AstraZeneca also signals how Belgian biotech companies can play a role in addressing global healthcare challenges. EsoBiotec’s platform technology for cell therapy responds to the growing demand for scalable, cost-effective treatment options, and the acquisition places this Walloon innovation in a global spotlight. For AMBT participants, it’s a reminder that science, strategy, and the right support can align to create a meaningful impact far beyond the lab.